Company intelligence / Profile preview

Innomane

Ownership: Private
Development stage: Other

Overview

InnoMane is a South Korean biotechnology company specializing in the development of first-in-class therapeutics for hair loss and skin regeneration. The company's core technology focuses on modulating the Wnt/beta-catenin signaling pathway, a key regulator of hair follicle development and tissue repair. InnoMane's research identified CXXC-type zinc finger protein 5 (CXXC5) as a negative regulator of this pathway; their drug candidates are designed to disrupt the interaction between CXXC5 and the Dishevelled (Dvl) protein. By activating Wnt signaling, these therapies aim to promote hair growth and treat various dermatological conditions. The company's lead program, IM-101, is currently in Phase 1 clinical trials for the treatment of androgenetic alopecia.

Therapeutic areas: Dermatology
Modalities: Small moleculePeptides
Industry: Biotech

Drug pipeline

1 asset

Diaronex

Unknown

Beyond the preview

Go deeper on Innomane.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innomane.